SHANGHAI, June 24,
2022 /PRNewswire/ -- Sanyou Biopharmaceuticals,
a biological high-tech enterprise focusing on R&D and services
of innovative antibody drugs, and Dragon Sail Pharmaceutical,
a CDMO and CMO enterprise dedicated to providing
world-leading high-end biological drug manufacture services,
announced a long-term strategic partnership taking effective. The
two parties will share their experiences and technical advantages,
and provide integrated and modular solutions that cover biological
drug R&D, CDMO and commercial productions to the
global biopharmaceutical industry.
Aiming to provide the pharmaceutical and biotechnology companies
with high-quality, high-efficiency and cost-effective drug
development and manufacturing services, the two companies will
invest their advantageous resources, expertise and experience
through this strategic partnership to carry out extensive
collaboration in the field of drug discovery, drug development and
CDMO. Sanyou will provide preclinical R&D services including
drug screening, pharmacology research, process development and
quality control of various biological drugs including monoclonal
antibodies, multi-specific antibodies, ADC drugs, etc. Dragon Sail
will provide services of pilot production, clinical sample
production, scale-up process development and commercial production
of various biological drugs.
Dragon Sail Pharmaceutical is a leading high-tech CDMO
enterprise for biological drug production in China, committed to provide one-stop R&D
and manufacturing outsourcing services from sequence to IND, and
from clinical sample production to BLA and commercial production.
With a total investment of 690 million
RMB and a total production scale of up to 12000L, the
company site is built and operated in compliance with NMPA and FDA
cGMP requirements and has passed the EU QP audit, which qualifies
for different stages of clinical sample and commercial drug
productions. The company has a professional technical team of over
200 staffs, with team members from well-known domestic and
international pharmaceutical companies and universities. 90% of the
current employees are technical R&D professionals, and about
40% of the employees own master and doctoral degrees. Equipped with
the advanced NONCROS® non-crossover antibody production technology,
Dragon Sail has provided high quality and efficient R&D and
manufacturing services to more than 10 pharmaceutical companies for
various biological drug projects.
Sanyou Biopharmaceuticals is a biological high-tech company
focusing on R&D and services of innovative antibody drugs.
Sanyou has established an integrated innovative antibody drug
R&D laboratory of more than 20,000 square meters with advanced
facilities in Shanghai Caohejing High-Tech Park. Driven by the
excellent innovation platforms of Super-Trillion Innovative
Antibody Drug Discovery Platform, Integrated Innovative Antibody
Drug R&D Platform and Intelligent Innovative Antibody Drug
R&D Platform, Sanyou has 10 major functional modules and more
than 40 core technological platforms covering preclinical R&D,
and has a professional team of more than 250 staffs, over 70% of
which holds a doctoral or master's degree. Sanyou has
provided high quality and high efficiency innovative antibody drug
development solutions, staged services and collaborative R&D to
more than 300 companies and organizations worldwide, and several
drug development projects above have entered the clinical
stages.
"We are honored to deepen and broaden our collaboration with
Sanyou" said Kai Tan, general
manager of Dragon Sail Pharmaceutical. "Sanyou has accumulated a
lot of successful experience in the discovery and development of
antibody drugs. Dragon Sail Pharmaceutical has established a
GMP-compliant cross-free manufacturing base in the new Lingang
District and has built a systematic development platform for
antibody drugs from DNA to BLA. The collaboration between the two
parties will provide a powerful engine for successful antibody drug
development, accelerate the new drug development process, empower
partners and benefit more patients."
"We highly value our strategic partnership with Dragon Sail
Pharmaceutical." said Guojun Lang,
CEO of Sanyou Biopharmaceuticals. "Dragon Sail's robust antibody
drug CMC development and GMP manufacturing platform has been
recognized by the industry. Sanyou has excellent innovative drug
discovery and preclinical R&D capabilities, and our proprietary
super-trillion innovative antibody drug discovery platform
integrates nine types of super-trillion innovative antibody
libraries with a cumulative library capacity of up to ten trillion,
and a high-throughput automated screening system. Sanyou will
combine the technical advantages with Dragon Sail Pharmaceutical to
provide more comprehensive and high quality one-stop services to
our clients."
About Dragon Sail Pharmaceutical
Dragon Sail was esatablished in 2016, directly invested by
Guilin Sanjin Pharmaceutical Company Limited and is one of the
wholly-owned subsidiaries of Sanjin. The aim of Dragon Sail is to
create a high-end monoclonal antibody drug cGMP and commercial
manufacturing sites in the Lingang Science Blue Bay (Shanghai). The total investment of this
manufacturing site is around 690 million
YUAN. The manufacturing scale of the first phase is 3*2000L
and the second phase could reach to 6*2000L scale. Dragon Sail
provides one-stop CDMO services for antibody drugs from CMC
development to Commercial Production, the site of Blue Bay is one
of the largest monoclonal antibody production bases in Shanghai.
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a biological high-tech
enterprise focusing on R&D and services of innovative antibody
drugs. Sanyou is committed to establishing a leading high-quality,
high-throughput, integrated R&D and value transformation
platform for innovative antibody drugs internationally,
constructing a business ecosystem involving therapy, R&D, and
diagnostic products and services, and cooperating with global
biopharmaceutical, diagnostic, and drug R&D companies to make a
new progress in the diagnosis and treatment of human diseases.
Sanyou has established an innovative antibody drug integrated
R&D laboratory of over 20,000 square meters with advanced
facilities and equipment, and more than 40 core innovation
technology platforms, including innovative antibody drug discovery
featured with a series of trillion phage display antibody
libraries, innovative antibody drug optimization, cell line
construction, upstream and downstream process development,
preclinical R&D and industrial development.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-forged-strategic-partnership-with-dragon-sail-pharmaceutical-to-upgrade-integrated-innovative-antibody-drug-rd-301574607.html
SOURCE Sanyou Biopharmaceuticals